Melissa R. Gibson practices intellectual property law with an emphasis on complex patent and Hatch-Waxman litigation.
Practice & Background
A lawyer in the firm’s intellectual property group, Ms. Gibson’s practice focuses on patent litigation, particularly in the pharmaceutical, biotechnology and chemical arts.
Prior to joining Akin Gump, Ms. Gibson worked for an intellectual property law firm, where she focused on all phases of Hatch-Waxman patent infringement litigation, including pre-suit investigation, pleadings, contentions, discovery, claim construction and depositions.
In addition to her patent litigation work, Ms. Gibson has successfully advocated for pro bono clients on a variety of matters, including challenging the wrongful termination of Section VIII subsidies through Article 78 proceedings and appealing the denial of FEMA assistance for individuals affected by Hurricane Sandy.
Ms. Gibson obtained her J.D. from Temple University Beasley School of Law, where she was a Merck Patent Fellow, President of the Intellectual Property Law Society and a participant in the Giles S. Rich Patent Moot Court competition.
Prior to law school, Ms. Gibson was a Research Biochemist at Merck and has significant experience in High-Throughput Drug Screening and Laboratory Automation. While working at Merck, Ms. Gibson received a Masters of Biotechnology degree from the University of Pennsylvania. She earned a B.S. in Chemical Engineering and Physical Science with a minor in Biomedical Engineering while participating in a dual degree program at Columbia University and Muhlenberg College.
Ms. Gibson’s recent engagements include:
- representing a pharmaceutical company in multiple Hatch-Waxman patent litigations involving patents directed to four oral contraceptive products
- advising a biopharmaceutical company on the strength of its patent portfolio for two injectable products in anticipation of potential patent litigations
- representing a pharmaceutical company in a Hatch-Waxman patent litigation relating to a drug preventing rejection of renal transplant.